Recursion Pharmaceuticals Stock Number Of Employees
| RXRX Stock | USD 6.68 0.20 3.09% |
Recursion Pharmaceuticals fundamentals help investors to digest information that contributes to Recursion Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Recursion Stock. The fundamental analysis module provides a way to measure Recursion Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Recursion Pharmaceuticals stock.
Recursion |
Recursion Pharmaceuticals Company Number Of Employees Analysis
Recursion Pharmaceuticals' Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Current Recursion Pharmaceuticals Number Of Employees | 800 |
Most of Recursion Pharmaceuticals' fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Recursion Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
| Competition |
Based on the recorded statements, Recursion Pharmaceuticals is currently employing 800 people. This is 92.73% lower than that of the Biotechnology sector and 49.43% higher than that of the Health Care industry. The number of employees for all United States stocks is 95.75% higher than that of the company.
Recursion Number Of Employees Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Recursion Pharmaceuticals' direct or indirect competition against its Number Of Employees to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Recursion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Recursion Pharmaceuticals by comparing valuation metrics of similar companies.Recursion Pharmaceuticals is currently under evaluation in number of employees category among its peers.
Recursion Fundamentals
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (40.45) % | ||||
| Current Valuation | 2.2 B | ||||
| Shares Outstanding | 395.07 M | ||||
| Shares Owned By Insiders | 3.59 % | ||||
| Shares Owned By Institutions | 77.01 % | ||||
| Number Of Shares Shorted | 75.45 M | ||||
| Price To Book | 2.60 X | ||||
| Price To Sales | 45.64 X | ||||
| Revenue | 58.84 M | ||||
| Gross Profit | (300.82 M) | ||||
| EBITDA | (426.72 M) | ||||
| Net Income | (463.66 M) | ||||
| Cash And Equivalents | 515.44 M | ||||
| Cash Per Share | 2.98 X | ||||
| Total Debt | 108.49 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 2.61 X | ||||
| Cash Flow From Operations | (359.17 M) | ||||
| Short Ratio | 2.51 X | ||||
| Earnings Per Share | (1.69) X | ||||
| Price To Earnings To Growth | (0.60) X | ||||
| Target Price | 9.0 | ||||
| Number Of Employees | 800 | ||||
| Beta | 0.85 | ||||
| Market Capitalization | 2.69 B | ||||
| Total Asset | 1.45 B | ||||
| Retained Earnings | (1.43 B) | ||||
| Working Capital | 526.8 M | ||||
| Net Asset | 1.45 B |
About Recursion Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Recursion Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Recursion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Recursion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.